Research map: Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study

Back to the article

Papers in this map

  1. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer · Myung‐Ju Ahn · 2023 · 580 citations · Cited by this paper
  2. Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation · Yang Li · 2026 · Cites this paper
  3. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  4. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study · Charles M. Rudin · 2016 · 579 citations · Cited by this paper
  5. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  6. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial · José Manuel Trigo · 2020 · 488 citations · Cited by this paper
  7. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · 2026 · Related
  8. Emerging therapies for small cell lung cancer · Sen Yang · 2019 · 444 citations · Cited by this paper
  9. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · 2026 · Related
  10. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions · Zsolt Megyesfalvi · 2023 · 368 citations · Cited by this paper
  11. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  12. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals · Ruili Wang · 2025 · 279 citations · Cited by this paper
  13. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  14. Small Cell Lung Cancer · So Yeon Kim · 2025 · 196 citations · Cited by this paper
  15. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  16. Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer · Akiko Tatematsu · 2008 · 191 citations · Cited by this paper
  17. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  18. BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study · Yuxiang Ma · 2024 · 151 citations · Cited by this paper
  19. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  20. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study · Martin Reck · 2024 · 81 citations · Cited by this paper
  21. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer · K Schmid · 2010 · 66 citations · Cited by this paper
  22. Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis · Demetrios Simos · 2013 · 63 citations · Cited by this paper
  23. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial · Charles M. Rudin · 2025 · 43 citations · Cited by this paper
  24. Assessment of targets of antibody drug conjugates in SCLC · Abhishek Ajay · 2025 · 37 citations · Cited by this paper
  25. Abstract 2642: BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation · Weili Wan · 2023 · 24 citations · Cited by this paper
  26. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial · Jianchun Duan · 2026 · 21 citations · Cited by this paper
  27. HER3 expression and MEK activation in non-small-cell lung carcinoma · Thubeena Manickavasagar · 2021 · 19 citations · Cited by this paper
  28. Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer · Shiling Zhang · 2023 · 11 citations · Cited by this paper
  29. Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer · Bingnan Zhang · 2025 · 2 citations · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper

Source: OpenAlex (CC0)